Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3492575 | 1.00 | ALDH1A1 (0.49) | ALDH1A1MAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL9002769 | 0.84 | ALDH1A1 (0.51) | ALDH1A1MAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4294768 | 0.84 | LMNA (0.47) | ALDH1A1MAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4294764 | 0.84 | LMNA (0.47) | ALDH1A1MAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL3493650 | 0.83 | TSHR (0.44) | MAPTKMT2AMEN1SMN1; SMN2NPC1 | |
| SCHEMBL3493043 | 0.83 | TSHR (0.44) | MAPTKMT2AMEN1SMN1; SMN2NPC1 | |
| SCHEMBL5120430 | 0.81 | TSHR (0.42) | ALDH1A1MAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5125735 | 0.80 | CASP1 (0.42) | ALDH1A1KMT2AMEN1LMNAGLA | |
| SCHEMBL5125736 | 0.80 | CASP1 (0.42) | ALDH1A1KMT2AMEN1LMNAGLA | |
| SCHEMBL11821119 | 0.79 | ALDH1A1 (0.56) | ALDH1A1MAPTKMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
| EP-1984355-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | Takeda Pharmaceutical Company Limited (JP) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007094513-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | ALDH1A1 1062/4885MAPT 4821/4885KMT2A 952/4885 |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | ALDH1A1 388/4885MAPT 3142/4885KMT2A 1049/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | ALDH1A1 388/4885MAPT 3142/4885KMT2A 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.